Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mifeprex Post-Marketing Restriction Compliance To Be Questioned By Rep. Souder

This article was originally published in The Pink Sheet Daily

Executive Summary

Danco Labs declined to testify at a hearing on deaths associated with the use of the abortifacient mifepristone.

You may also be interested in...



Corcept’s Second Corlux Phase III Trial Enrolled For Psychotic Major Depression

Company expects data from three Phase III trials of mifepristone for PMD by year-end.

Corcept’s Second Corlux Phase III Trial Enrolled For Psychotic Major Depression

Company expects data from three Phase III trials of mifepristone for PMD by year-end.

GOP Lawmakers Seize On Adverse Event Analysis, Push For Mifeprex Withdrawal

Rep. Bartlett (R-Md.) is seeking to revitalize support for the “RU-486 Suspension & Review Act.”

Topics

UsernamePublicRestriction

Register

PS064178

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel